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Aim: Biophenol-rich nutraceuticals may be an adjuvant treatment for Crohn's
disease (CD), ulcerative colitis (UC), symptomatic uncomplicated diverticular
disease (SUDD), and irritable bowel syndrome (IBS). This systematic review
and meta-analysis aimed to determine the efficacy and safety of biophenol-rich
nutraceutical supplementation on CD, UC, SUDD, and IBS on gastrointestinal
symptoms (GIS), quality of life (QoL), inflammatory and oxidative stress bio-
markers, and adverse events compared to usual care or placebo.
Methods: PubMed, Embase, CINAHL, and CENTRAL were searched for
randomised controlled trials until 27 April 2020. Outcomes were GIS, inflam-
matory and oxidative stress markers, QoL, and adverse events. The Cochrane
Risk of Bias tool and GRADE were used to appraise studies. Data were pooled
using Revman.
Results: Twenty-three trials in CD, UC, and IBS patients were included. Com-
pared with placebo, biophenol-rich nutraceuticals improved GIS (SMD: 0.43
[95%CI: 0.22, 0.63]; GRADE: very low) in UC, CD, and IBS participants. In UC
and CD participants, biophenol-rich nutraceuticals improved CRP by 1.6 mg/L
[95%CI:0.08, 3.11; GRADE: low], malondialdehyde by 1 mmol/L [95%CI:0.55,
1.38; GRADE: low]; but only resveratrol improved QoL (SMD: −0.84 [95%CI:
−1.24, −0.44; GRADE: high). Resveratrol (for UC and CD participants) and
peppermint oil (for IBS participants) had greater certainty in the evidence for
improving GIS and QoL (GRADE: moderate to high). There was no effect on
adverse events (P > .05).
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Conclusions: Biophenol-rich nutraceuticals may be an effective and safe adju-
vant treatment for the management of CD, UC, and IBS; with higher certainty
of evidence for resveratrol for UC and CD and peppermint oil for IBS.
KEYWORD S
Crohn disease, diverticular diseases, inflammatory bowel diseases, irritable bowel syndrome,
polyphenols, ulcerative colitis
1 | INTRODUCTION
Inflammatory-related gastrointestinal conditions, such as
Crohn's disease (CD), ulcerative colitis (UC), symptom-
atic uncomplicated diverticular disease (SUDD), and irri-
table bowel syndrome (IBS), are an emerging global
health concern, with incidence and prevalence predicted
to increase worldwide.1-3 Although CD, UC, SUDD, and
IBS all have unique pathophysiology, they share gastroin-
testinal symptoms such as abdominal pain, cramping,
bloating, diarrhoea, and/or constipation.4-6 Inflammation
and/or oxidative stress play a role in the pathophysiology
of CD, UC, SUDD7,8; however, not consistently in IBS.9
From the patient perspective, burden is often introduced
not only by the percieved symptoms, but lifelong finan-
cial and personal costs and treatment side effects, leading
to reduced quality of life and suffering.10-12 The rising
prevalence of these conditions and subsequent
hospitalisations also present a substantial burden to
health-care systems.13
Current therapies for the treatment and management
of inflammation-related gastrointestinal conditions
include a variety of medical, diet, and lifestyle recom-
mendations14-17; however, biophenols have recently
gained interest as a possible adjuvant therapy for a range
of conditions.18-20 Biophenols, sometimes referred to as
polyphenols, are phytochemicals found in foods such as
extra virgin olive oil, peanuts, turmeric, ginger, tea, and
peppermint. Although polyphenols are the more com-
mon term for such phytochmicals, they represent only
phenolic compounds with two or more aromatic benzene
rings.21 Recently, there has been a move towards utilising
the more scientifically accurate term of biophenols,
which represent all plant-derived phenols.21 The benefits
of biophenols have been suggested for the treatment of
chronic conditions in humans, such as decreasing toxicity
in hemodialysis, improving mental health and cognitive
performance, managing nausea and vomiting in chemo-
therapy, or reducing cardiovascular disease risk.19,22-27
The beneficial effects of biophenols are due to a vari-
ety of mechanisms, including their antioxidant,
antiglycation, and anti-inflammatory activities on glucose
and lipid metabolism as well as cell proliferation and
interactions with the gut microbiota.28-30 More recently,
there is a growing body of interventional research
exploring the potential of biophenol-rich nutraceuticals
on patient-centered outcomes in gastrointestinal condi-
tions.31,32 However, the efficacy and safety of biophenol-
rich nutraceuticals for such conditions has not been sys-
tematically reviewed and certainty in the body of evi-
dence for their adjuvant treatment potential is unknown.
This systematic review and meta-analysis aimed to
determine the efficacy and safety of biophenol-rich nutra-
ceutical supplementation on CD, UC, SUDD, and IBS on
gastrointestinal symptoms (GIS), quality of life (QoL),
inflammatory and oxidative stress biomarkers, and
adverse events compared to usual care or placebo.
2 | METHODS
This systematic review was written in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines33 and was pro-
spectively registered with the International Prospective
Register of Systematic Reviews (PROSPERO: 159820).
Relevant studies were identified through a systematic
search of the Cochrane Central Library, Medline (via
PubMed), Embase (via Ovid), and CINAHL databases for
articles published since database inception to 27 April
2020. Controlled vocabulary search terms were used
where appropriate to describe major biophenol classes,
disease states, and study designs in combination with
keywords (Table S1). A snowball search was also con-
ducted, whereby reference lists of included studies and
similar reviews were considered to identify additional
studies not found in the systematic search strategy, up
until 9 December 2019.
Inclusion criteria for participants were human adults
aged ≥18 years with CD, UC, SUDD, or IBS. Where age
range was not reported, samples were included if the
mean age was ≥18 years. Inclusion criteria for types of
studies were parallel or crossover randomised controlled
trials (RCTs). Studies were included if the intervention
group were treated with an orally consumed biophenol-
rich nutraceutical with no coadministration of any test
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product or therapy beyond standard care for more than
1-week. Biophenol-rich nutraceuticals were included if
the test product was listed on the Phenol-Explorer 3.6
database, which is an independent database compiling
over 500 biophenols.34 Studies were included if compara-
tor groups were treated with standard care alone (if this
standard care was also provided to the intervention
group) or placebo. Studies were included if they were
published in languages spoken by the authorship team
(English and Chinese). Studies in other languages were
included only if they could be translated to English using
Google Translate Software.35 Exclusion criteria for study
designs were review or observational studies, studies that
did not report associated outcomes, or studies which did
not undergo peer review (ie, grey literature, conference
papers, abstracts).
Following study deduplication using DeDuplicate,36
EndNote,37 and Covidence 2019,38 the initial title and
abstracts screening, then full-text screening of articles,
was conducted on Covidence by two investigators inde-
pendently. Disagreements between reviewers were
resolved by consensus or third investigator.
The primary outcome of interest was GIS; and sec-
ondary outcomes were inflammatory markers (e.g.,
C-reactive protein (CRP), calprotectin, interleukin-6 (IL-
6), interleukin-8 (IL-8)), oxidative stress markers, QoL,
and adverse events. Adverse events were considered any
patient-reported side effect related or potentially related
to the intervention or control conditions.
Data were extracted from relevant studies using the
following parameters: author/date, study design, sample
size and attrition, study duration, sample demographics
(eg, age, sex, type of gastrointestinal condition), interven-
tion characteristics (type of biophenol, dosing regimen,
duration), and outcomes as described above. Extracted
continuous outcome data were baseline, follow-up, and
change measure of central tendency (mean or median),
variation or precision (SD, SE, or 95% confidence inter-
vals (CI)) for both groups as well as P-value for change
over time and between groups. If mean change was not
reported, it was calculated and the SD of the change was
estimated using the Review Manager calculator (Versions
5.3 Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2012).39 Extracted categorical
outcome data were number of events. Data were
extracted by a single investigator and checked for accu-
racy by a second investigator, as were calculated data.
Internal study quality was assessed using the
Cochrane Risk of Bias tool, which included assessing ran-
dom sequence generation, allocation sequence conceal-
ment, blinding, and incomplete outcome data.40 Risk of
bias was assessed independently by two researchers.
Certainty in the body of evidence informing the esti-
mated effect was assessed via the Grading of Recommen-
dation, Assessment, Development and Evaluation
(GRADE) assessment tool.41 Although GRADE may be
applied to meta-analysed or narratively synthesised data;
due to the large number of potential outcomes included
in this study only meta-analysed outcomes were assessed
via GRADE. Certainty in the body of evidence was
judged by considering risk of bias, inconsistency, indi-
rectness, imprecision, publication bias, effect size, dose-
response, and plausible confounding. Considering these
factors, each pooled outcome was rated as having high,
moderate, low, or very low certainty. The GRADE cer-
tainty in the estimated effect sizes was assessed by two
investigators independently and judgements were con-
firmed by a third investigator. Publication bias was
assessed via funnel plot.
Outcome data were pooled where adequately reported
change data (i.e., difference from baseline to follow-up)
was available or could be calculated for two or more
interventions using Review Manager (Versions 5.3
Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2012).39 Continuous outcomes
were pooled using the inverse variance test and reported
as mean difference or standardised mean difference
(SMD) if different scales/measurement tools were used.
SMD effect sizes of <0.4 were considered small, 0.4 to 0.7
moderate, and >0.7 large.42 Pooled categorical outcomes
were assessed using Mantel-Haenszel test and reported as
odds ratios (OR). Heterogeneity was evaluated with the I2
statistic, where a value >50% was considered to represent
substantial statistical heterogeneity.43 P < .05 was consid-
ered as statistically significant. Pre-registered sensitivity
analyses were undertaken in models with substantial sta-
tistical heterogeneity using participant demographics,
study quality, differences in measurement tools, interven-
tion factors, or confounding variables. Type of
inflammatory-related gastrointestinal condition and type
of nutraceutical administered were explored for signifi-
cant subgroup effects.
3 | RESULTS
The systematic search identified 3008 records and a fur-
ther four were identified through the snowball search.
After deduplication and title/abstract screening, the full
text of 93 articles were evaluated for eligibility and
23 were included (Figure S1). Most RCTs had a low to
unclear risk of bias and two studies had a high risk of
bias (Figure 1; justifications Table S2). There were
10 RCTs included where funding was received from a
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source with a potential interest in a positive result
(Tables 1 and 2).
All 23 included RCTs were placebo-controlled; 21 were
parallel and two were cross-over (Tables 1 and 2). Two
parallel RCTs in participants with IBS had two interven-
tion groups; therefore, a total of 25 interventions arms
were included. Most of the studies were from Iran (n = 10
RCTs), followed by the United States (n = 2 RCTs), and
Italy (n = 2 RCTs). All other RCTs were from different
countries across Europe, the Middle East, and Asia.
Total study sample sizes ranged from n = 1658 to
n = 18963 (N = 1566 total participants; Tables 1 and 2).
Of the 25 interventions, 16 (64%) recruited participants
with active IBS (Table 2), seven (28%) with mild to mod-
erate UC, and two (8%) with inflammatory bowel disease
(IBD; i.e., UC or CD) (Table 1). No included RCT rec-
ruited participants with SUDD.
Peppermint oil was the most studied intervention
(n = 5 RCTs in IBS participants), followed by ginger
(Zingiber officinale) (n = 2 RCTs in IBS participants,
n = 1 RCT in IBD participants), resveratrol (n = 2 RCTs
in IBD participants), and aloe vera (n = 1 RCT in IBS par-
ticipants, n = 1 RCT in IBD participants). Four RCTs, all
in IBS participants, used an intervention product com-
posed of mixed biophenols (a blend of two to four
biophenols in powder or capsule form). Other interven-
tions were reported by a single study (curcumin, wheat
grass, anise oil, soy isoflavones, mastic tree (Pistacia
lentiscus), yarrow (Achillea wilhelmsii C. Koch), pome-
granate peel; Tables 1 and 2). Study durations ranged
from 2 to 12 weeks. The most common mode of nutra-
ceutical delivery was capsule form (n = 17 RCTs, 74%).
Other modes of delivery included tablet (n = 2 studies),
drink (n = 2 studies), syrup (n = 1 study), and gel form
(n = 1 study). Of the four studies that reported compli-
ance, adherence to the prescribed supplements ranged
from 67%64 to 100%50,51,56 with no difference between
intervention and control groups (P > .05).
Gastrointestinal symptom scores were measured
using condition-specific tools including visual analogue
scales (VAS), Irritable Bowel Syndrome Symptom Scoring
Scale, the Simple Clinical Colitis Activity Index, the Dis-
ease Activity Index, Lichtiger Colitis Activity Index, Par-
tial Mayo Score, and Harvey-Bradshaw Index (Table 2).
Twenty-three intervention groups assessing GIS that
were able to be pooled with meta-analysis used yarrow,
aloe vera, curcumin, mastic tree, pomegranate peel, res-
veratrol, ginger, anise oil, peppermint oil, soy isoflavones,
or mixed biophenols.
Meta-analysis found that compared with placebo,
biophenol-rich nutraceuticals significantly improved
GIS with a moderate effect size (SMD: 0.43 [95%CI:
0.22, 0.63], P < .0001, I2: 64%, GRADE: very low; Table
S3, n = 18 studies, n = 21 intervention groups, n = 1187
participants; Figure 2). Sensitivity analysis did not
FIGURE 1 Risk of bias summary of randomised controlled
trials examining the effect of biophenol-rich nutraceuticals on
gastrointestinal symptoms and related outcomes in adults with
inflammatory related gastrointestinal conditions





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 GIANG ET AL.
TABLE 2 Characteristics and findings of n = 14 included randomised controlled trials which examined orally consumed biophenol-rich
nutraceuticals in participants with irritable bowel syndrome
Characteristics Intervention Comparator Outcomesa
Aloe vera54
DBPCRCT, 2-arms, parallel:
Sweden, N = 68 (IG = 33,
CG = 35), 7.4% attrition.
IBS: 75%F, IG: μ43.9 y, μ44.2 y.
No funding or COI reported.
n = 32 at FU.
Type: 250 mg Aloe barbadensis
Mill. Extract (AVH200), 60 mg
ascorbic acid dissolvable tablet.
Dose: 500 mg/d (250 mg BD).
Duration: 4-weeks.
n = 31 at FU.
Type: 60 mg ascorbic acid and
excipients dissolvable table.
Dose: 120 mg/d (60 mg BD).
Duration: 4-weeks.
GIS—IBS-SSS (scoreb): IG:
baseline 315 ± 83, FU: 257 ±
107, change −58 ± 1.1.9, P =
.003. CG: baseline 276 ± 88,
FU: 253 ± 100, change −23 ±
69.0, P > .05. P = .03 between
groups.
Anise oil55
DBPCRCT, 3-arms [2 eligible],
parallel: Iran, N = 80
(IG = 40, CG = 40), 6.25%
attrition.
IBS: 48.8%, IG μ34.15 y, CG
μ32.35 y.
No funding or COI declared.
n = 38 at FU.
Type: Enteric coated anise oil
capsule.
Dose: 600 mg/d (200 mg TDS).
Duration: 4 weeks.
n = 37 at FU.








5.97 ± 2.35, FU 1.82 ± 1.43,
change −4.15 ± 4.8. CG:
baseline 5.27 ± 2.12, FU
3.33±1.74, change −1.94 ± 2.7.
P < .0001 between groups.
Quality of life—IBS-QOL
(scorec): IG: baseline
86.20 ± 27.13, FU 64.38±23.10,
change −21.8. CG baseline
83.30 ± 21.64, FU 72.82±18.20,





N = 60 (IG: n = 30, CG:
n = 30), 0% attrition.
IBS-D: 73%F, μ35 y.
No funding or COI declared.
n = 30 at FU.
Type: Gelsectan capsule
(containing xyloglucan, pea
protein and tannins from grape
seed extract, and xylo-
oligosaccharides)
Dose: not clear, 1 capsule BD.
Duration: 28 days.
n = 30 at FU.
Type: Placebo capsule (not clear).
Dose: not clear, 1 capsule BD.
Duration: 28 days.
Adverse events: IG: n = 0/30,
CG: n = 0/30.
GIS—incidence normal stools: IG
baseline 1/60, FU 54/60,
P = .0019. CG baseline 26/60,
FU 7/60, P = .0001.
On day 28, the proportion of
patients with normal stools,
GIS—IBS-D incidence abdominal
pain: IG baseline 38/60, FU: 0/
60, P = .002. CG 25/60, FU 27/
60, P = .027.
GIS—IBS incidence bloating: IG
baseline 38/60, FU 1/60,
P = .028. CG baseline 25/60,
FU 27/60, P = .041.






N = 30 (IG: n = 15, CG:
n = 15), n = 11 (34%)
attrition.
IBS-D: 59%F, μ50.3 ± 11.9 y.
No funding or COI declared.
n = 20 in the second phase; n = 5
in the third phase.
Type: Ayurvedic herbal
compound preparation made
from curry (Murraya Koenigii),
pomegranate (Punica
granatum) and turmeric
n = 6 in the second phase.
n = 17 in the third phase.
Type: Placebo (hay Graminis




Adverse events: IG: n = 9/15. CG:
n = 4/15.
GIS—IBS-SSS (scoreb): IG:
baseline 217.4 ± 91.4, FU:
220.3 ± 90.0, change
2.9 ± 33.64, P = .74. CG:
baseline
(Continues)
GIANG ET AL. 9
TABLE 2 (Continued)
Characteristics Intervention Comparator Outcomesa
(Curcuma longa) in a 6:3:1
ratio.
Dose: 10 g (5 g of powder
dissolved in 100 mL of warm
water BD).
Duration: 4 weeks.
226.0 ± 81.8, FU 215.0 ± 89.9,
change −11 ± 33.64, P = .23.
No significant differences
between the IG and CG phases.
Quality of life—IBS-QOL
(scorec): IG: baseline
69.9 ± 21.6, FU: 72.1 ± 19.0,
2.2 ± 65.83, P = .89. CG:
baseline 68.2 ± 19.1
CG: FU 67.4 ± 22.3, change




United States, N: 16 (IG:
n = 8, CG: n = 8), n = 3
(19%) attrition.
IBS-C: 81%F, μ38 y (23-57 y).
Funding and authors affiliated
with test product.
n = 7 at FU.
Type: blended extracts in capsule
(Quebracho, Conker tree, M.
balsamea Willd, peppermint
oil).
Dose: Quebracho 150 mg (80-82%
polyphenol content), Conker
tree—470 mg (20% saponin
content), M. balsamea Willd
oil—0.2 mL; pure peppermint
oil (content quantity not
specified).
Duration: 2 weeks.








2.62±0.886, P < .001. CG:
change 0.28 ± 0.39, P = .141.
Mixed biophenols59
DBPCRCT, 2-arms, parallel:
Italy, N = 21 (IG n = 60, CG
n = 61), 4.1% attrition.
IBS: 63.6%F, IG μ41.4 y, CG
μ39.4 y.
Funding associated with test
product. No COI declared.
n = 58 at FU.
Type: blended essential oils
(curcumin and fennel) capsule.
Dose: 84 mg/d curcumin and
50 mg fennel essential oil




n = 58 at FU.
Type: Placebo capsule.
Dose: not clear BD.
Duration: 4 weeks.
Adverse events: IG: 1.7%. CG
3.4%.
GIS—IBS-SSS (scoreb): IG:
baseline 255.7 ± 39.9, FU:
127.8 ± 77.4, change
−127.9 ± 119.89. CG: baseline
263.2 ± 34.3, FU: 195.5 ± 88.0,
change −67.7 ± 119.89.
P < .001. P < .05 between
groups.
Quality of life—IBS-QOL
(scorec): IG: change 17.4 ±




Italy, N = 57 (IG: n = 28, CG:
n = 29), n = 7 (12%) attrition.
IBS: 76%F, μ41 y (20–60).
No funding or COI declared.




Dose: 550 mg (225 mg
peppermint oil +45 mg of
Natrasorb BD).
Duration: 4 weeks.
n = 26 at FU.
Type: Placebo capsules.
Dose: 55 mg maltodextrin
(225 mg of maltodextrin with
mint flavour BD).
Duration: 4 weeks.
Adverse events: IG: n = 1/24. CG:
n = 0/26.
GIS—incidence ≥50% reduction
of total IBS symptoms score:
IG: n = 18/24, P < .01. CG:




United States, N = 72 (IG:
n = 34 at FU.
Type: Peppermint oil capsules.
Dose: 540 mg (180 mg TDS).
n = 36 at FU.
Type: Placebo capsules.
Dose: NR TDS.
Adverse events: IG: n = 2/34,
CG: n = 4/36.
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TABLE 2 (Continued)
Characteristics Intervention Comparator Outcomesa
n = 35, CG: n = 37), n = 2
(2.7%) attrition.
IBS-M and IBS-D: 75%F, IG
μ40.2 y, CG μ41 y.
Independently funded. COI
declared.
Duration: 4 weeks. Duration: 4 weeks. GIS—TISS (scoreb): IG: change
−1.16 ± 0.897, P = .0246. CG:
change −0.70 ± 0.737.
GIS—incidence of severe
symptoms: IG change −66.8%.




China, N = 110 (IG: n = 55,
CG: n = 55), n = 9 (8.1%)
attrition.
IBS: 40%F, 18-70 y.
Funding and COI were not
described.
n = 52 at FU.
Type: Enteric coated peppermint
oil capsule
Dose: 561-748 mg/d (187 mg/
capsule x 3-4/d)
Duration: 4-weeks.
n = 49 at FU.
Type: Placebo capsule
Dose: 3-4/d, dose not reported.
Duration: 4-weeks.
GIS—Incidence abdominal pain:
IG: n = 41/51(79%) participants
improved. CG: n = 21/49(43%)
participants improved.
Significant difference between
groups (P < .05).
Peppermint oil63
DBPCRCT, 3-arms, parallel:
Netherlands, N = 189
(unclear number of patients
in each group), 5.8% attrition.
IBS: 78%F, μ34.4 y.
No funding or COI declared.
IG 1: n = 62 at FU.
Type: Peppermint oil capsule.
Dose:182 mg/d (60.3 mg TDS).
Duration: 8-weeks.
IG 2: n = 62 at FU.
Type: Peppermint oil capsule.
Dose:182 mg/d (60.3 mg TDS).
Duration: 8 weeks.




Adverse events incidence: IG1





−91.53±66.28, P = .00. IG2
baseline 285.42±92.47, FU
201.05±120.17, change
−84.37±63.34 P = .00. CG
baseline 276.53±93.44, FU
226.80±119.76, change
−49.73 ± 66.28, P = .00.
P = .020 between IG1 and CG.
P = .22 between IG2 and CG.
Quality of life—IBS QOL (scorec):
IG1: baseline 68.8 ± 2.6, FU:
75.9 ± 2.6, change 7.1,
P = .066. IG2: baseline
69.8 ± 2.5, FU 75.5 ± 2.5,
change 5.7, P = .374. CG




Iran, N = 0 (IG = 45,
CG = 45), 33.3% attrition.
IBS: 75%F, μ36 y.
Independently funded. COI not
described.
n = 33 at FU.
Type: Peppermint oil capsule
Dose: 546 mg/d (182 mg TDS).
Duration: 8 weeks.




Adverse events: IG: n = 19/33.
CG n = 14/27.
GIS—incidence abdominal pain
free: IG: baseline n = 0/33, FU
n = 14/33. CG: baseline n = 0/
27, FU n = 6/2. P < .001
between groups.
Quality of life—SF-36 (scorec): IG
baseline 57.8 ± 29.3, FU:
63.0 ± 28.2. CG baseline
48.9 ± 29.8, FU: 53.7 ± 26.4.




n = 22 at FU.
Type: Soy isoflavones capsule
n = 23 at FU. Adverse events: IG: n = 0/22. CG:
n = 0/23.
(Continues)
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TABLE 2 (Continued)
Characteristics Intervention Comparator Outcomesa
N = 67 (IG: n = 35, CG:
n = 32), n = 22 (33%)
attrition.
IBS: 72%F, IG: μ45.5 y, CG:
40.0 y.
Independently funded. No COI
declared.
Dose: 40 mg of isoflavones
(10 mg of diadzein, 8.5 mg
genistein, 1.5 mg glycetin BD).
Duration: 6 weeks.
Type: Placebo capsule (corn
starch).
Dose: 1 capsule BD.
Duration: 6 weeks.
GIS—IBS-SSS (scoreb): IG: baseline
23.64 ± 8.17, FU: 12.77 ± 8.16,
change −10.87 ± 7.85, P= .00.
CG: baseline 24.78 ± 11.82, FU:
19.74 ± 12.08, change





64.41 ± 27.78, FU
41.68 ± 28.47, change
−22.73 ± 228.31, P = .65. CG:
baseline 46.70 ± 31.37, FU:
44.17 ± 33.47, change
−2.53 ± 228.31, P = .96.
P = .009 between groups.
Ginger (Zingiber officinale)66
DBPCRCT, 3-arms, parallel:
Iran, N = 50 (IG = 25,
CG = 25), 2% attrition.
IBS: age and sex NR.
Funding and COI NR.












Adverse events: IG: 16.7%. CG:
35.7%.
GIS—IBS-SSS (scoreb): IG1:
baseline 260.0 ± 65.5, FU:
191.3 ± 95.8, change
−68.7 ± 84.3, P = .007. IG2:
baseline 222.7±53.3, FU:
198.9 ± 88.9, change
−23.8 ± 73.9, P = .233. CG:
baseline 253.2 ± 65.9, FU:
165.0±49.3, change—
88.2 ± 78.2, P = .001. P > .05
between groups.
Ginger (Zingiber officinale)67
DBPCRCT, 3-arms (2 eligible),
parallel: Iran, N = 45 (IG1
n = 15, CG n = 15), 0%
attrition.
IBS: age and sex NR.
No funding or COI declared.
IG2: n = 15 FU.




n = 15 at FU.






39.6 ± 3.29, FU: 31.73 ± 3.21,
change −7.9 ± 13.5, P < .05.
CG: baseline 42.46 ± 2.94,
change −4.8 ± 8.7, FU:
37.66 ± 2.89, P > .05.
GIS—Abdominal distention
severity (scoreb): IG: baseline
68.73 ± 3.68, FU: 50.00 ± 2.88.




70.66 ± 3.09, FU: 49.13 ± 2.7.
Abbreviations: BDS, twice daily; CG, control group; COI, conflict of interest; CRP, c-reactive protein; d, day; DBPCRCT, double blind placebo controlled
randomied controlled trial; F, female; FU, follow-up; GIS, gastrointestinal symptoms; IBS, irritable bowel syndrome; IBS-c, irritable bowel syndrome
constipation dominant; IBS-d, irritable bowel syndrome diarrhoea dominant; IBS-m, irritable bowel syndrome mixed constipation and diarrhoea; IBS-SSS,
irritable bowel syndrome symptom scoring scale; IG, intervention group; IQR, interquartile range; 4ITT, intention to treat; NR, not reported; QDS, four times
daily; QOL, quality of life; SF-36, short form 36; TDS, thrice daily; TISS, total IBS symptom score; VAS, visual analogue scale; y, years.
aContinuous outcome data reported as mean (μ) ± standard deviation and categorical outcome data reported as number of events/number of participants,
unless otherwise specified.
bHigher scores indicate worse symptoms.
cHigher scores indicate better symptoms.
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FIGURE 2 Gastrointestinal symptoms of adults with inflammatory bowel disease or irritable bowel syndrome after treatment with
biophenol-rich nutraceuticals or placebo per nutraceutical type
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substantially improve statistical heterogeneity. GIS
were not different according to subgroup by type of con-
dition (IBD vs IBS; P = .52). Four studies that recruited
participants with IBS measured GIS incidence; all of
which reported significant improvements in the inter-
vention (n = 3 studies used peppermint oil, n = 1 study
used a mixed biophenol formulation (gelsectan)
(Table 2). There were sufficient studies pooled for GIS
to generate a funnel plot, which suggests some positive
effects of the intervention have not been published
(Figure S2).
Subgroup analysis of nutraceutical type found signifi-
cant differences in GIS between groups (P = .02, I2: 53%).
Compared with placebo, peppermint oil significantly
improved GIS in participants with IBS with a moderate
effect size (SMD: 0.57 [95%CI: 0.35, 0.80], P < .0001, I2:
0%, n = 2 studies, n = 3 intervention groups, n = 322 par-
ticipants, GRADE: moderate, Figure 2) and resveratrol
improved GIS in participants with IBD with a large effect
size (SMD: 1.10 [95%CI: 0.68, 1.51], P < .00001, I2: 0%,
n = 1 study, n = 2 intervention groups, n = 105 partici-
pants, GRADE: moderate, Figure 2). Other nutraceutical
types with two or more interventions which showed no
significant effect on GIS were aloe vera (SMD: 0.17 [95%
CI: −0.36, 0.70], P = .53, I2: 46%, n = 2 studies, n = 2
intervention groups, n = 113 participants, GRADE: very
low, Figure 2), mastic tree (SMD: 0.21 [95%CI: −0.30,
0.72], P = .42, I2: 34%, n = 1 study, n = 2 intervention
groups, n = 92 participants, GRADE: very low, Figure 2),
ginger (SMD: 0.03 [95%CI: −0.67, 0.73], P = .94, I2: 75%,
n = 3 studies, n = 4 intervention groups, n = 136 partici-
pants, GRADE: very low, Figure 2), and mixed
biophenols (SMD: 0.71 [95%CI: −0.45, 1.87], P = .23, I2:
86%, n = 3 studies, n = 3 intervention groups, n = 166
participants, GRADE: very low, Figure 2).
Quality of life was mostly measured with condition
specific tools such as the Inflammatory Bowel Disease
Questionnaire and the Irritable Bowel Syndrome Quality
of Life (Table 2). Pooling 12 intervention groups which
measured and reported QoL (Tables 1 and 2) found that
biophenol-rich nutraceuticals did not improve QoL com-
pared with placebo (SMD: −0.18 [95%CI: −0.41, 0.06],
P = .14, I2: 62%; GRADE: very low; Table S3). Condition
subgroups were not significantly different (IBD vs IBS;
P = 0.32); however, a significant subgroup difference was
found with nutraceutical type (P = .002, Figure S3). Com-
pared with placebo, resveratrol significantly improved
QoL in participants with IBD (SMD: −0.84 [95%CI:
−1.24, −0.44], P < .0001, I2: 0%, n = 2 studies, n = 2
intervention groups, n = 105 participants, GRADE: high,
Figure S3). Other nutraceutical types with two or more
interventions, which showed no significant effect on QoL
were peppermint oil and mixed biophenols.
No studies which recruited participants with IBS
measured inflammatory or oxidative stress markers. The
pro-inflammatory marker CRP was reported by four stud-
ies (participants with UC: n = 3 studies, UC and CD:
n = 1 study). Interventions assessing CRP used yarrow,
mastic tree, resveratrol, or aloe vera. Compared with pla-
cebo, biophenol-rich nutraceuticals significantly
improved CRP by 1.6 mg/L (95%CI: 0.08, 3.11; P = .04; I2:
18%, GRADE: low;Table S3, n = 4 studies, n = 4 inter-
ventions, n = 193 participants). Compared with placebo,
biophenol-rich nutraceuticals (resveratrol (n = 1 study)
and ginger (n = 1 study)) significantly improved oxidative
stress marker malondialdehyde by 1 mmol/L ([95%CI:
0.55, 1.38]; P < .00001; I2: 0%, n = 2 studies, n = 2 inter-
ventions, n = 102 participants; GRADE: low) but had no
effect on total antioxidant capacity (SMD: 1.36 [95%CI:
−0.24, 1.30], P = .17 I2: 73%, 2 studies, 2 interventions,
102 participants; GRADE: very low). Too few studies
were included in these models to conduct a sensitivity
analysis. One study reported significant positive effects of
resveratrol on inflammatory marker, tumour necrosis
factor alpha,51 and oxidative stress marker, superoxide
dismutase.50 Other oxidative stress markers measured
were oxidised LDL, which was significantly improved
with mastic tree. Other inflammatory markers measured
were IL-6, IL-10, and calprotectin, which showed no sig-
nificant effect (Table 1).47,48
Adverse events were reported in 19 studies. A total of
46 and 80 adverse events were reported in control and
intervention groups, respectively; however, when pooled,
there was no significant difference between groups (OR:
0.68 [95%CI: 0.40, 1.15], P = .15, I2: 21%; GRADE: low;
Table S3). Adverse events were not different according to
subgroup by type of condition (IBD vs IBS; P = .27) or
nutraceutical type (P = .16). Adverse events were mild
and mostly included gastrointestinal distress. No serious
adverse events were reported.
4 | DISCUSSION
This review found that adjuvant biophenol-rich nutraceu-
tical supplementation may improve GIS, inflammation,
oxidative stress, and QoL in adults diagnosed with IBD,
and GIS in participants diagnosed with IBS. Using the
GRADE framework, there was low certainty that the
pooled effect sizes represent the true effect due to statisti-
cal heterogeneity, publication bias, and/or imprecision.
Factors leading to the substantial clinical heterogeneity
included varying medical status, pathophysiology of the
gastrointestinal condition, and lifestyle of participants as
well as the use of different outcome measurement tools
and biophenol sources. Subgroup analyses resolved some
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sources of heterogeneity, and found high certainty that
resveratrol improved QoL in IBD with a large effect size,
and moderate certainty that peppermint oil and resvera-
trol improved GIS with moderate and large effect sizes
for IBS and IBD, respectively.
The pooled effect size of all biophenols on GIS was
moderate (SMD 0.43), suggesting substantial clinical ben-
efit of intervention, particularly peppermint oil and res-
veratrol. Despite the use of validated tools in measuring
GIS, it is important to recognise that there is no univer-
sally accepted endpoint to assess GIS severity. This is due
to several factors including the subjectivity of GIS experi-
enced by patients, variations in the types of rating scales
such as VAS vs Likert scales, the treatment of scales as
continuous or ordinal, and the ceiling and floor effects of
different tools.68 Although the inconsistency found in the
pooling of GIS scores across the 21 intervention groups
may be contributed to by the pooling of patients with IBS
and IBD, two distinct conditions, subgroup analysis did
not identify any statistically significant difference in their
perceptions of GIS. Publication bias contributed to the
decreased certainty in the effect on GIS; however, the
direction of bias suggests that the true effect size may be
larger than the estimate.
The evidence supporting the use of biophenol-rich
nutraceuticals for subjective GIS improvement in IBD is
strengthened by the finding of decreased objective
inflammatory and oxidative stress biomarkers. Previous
studies have shown the effect of biophenol-rich
nutraceuticals on improving oxidative stress and inflam-
mation in chronic disease states including liver disease,
cardiovascular disease, and kidney disease.19,27,69
Although only measured by few studies with a limited
cumulative sample size and wide confidence intervals,
decreasing certainty in the estimated effects, this finding
may explain the mechanism by which GIS were
improved.70 Although inflammatory and oxidative stress
markers are not consistent biomarkers for IBS, future
studies should measure these outcomes to better explore
how inflammation and oxidative stress may play a role
within IBS subtypes and if these may be modified by
biophenols.
Emerging evidence suggests that biophenols may ben-
eficially modulate inflammation, oxidation, and the gut-
brain axis via stimulation of the abundance of health pro-
moting bacterial species and inhibition of pathogenic spe-
cies in the gut.71 Gut bacteria metabolites are linked to
having important roles in reducing inflammation and
oxidation as well as maintaining the health of gastroin-
testinal cells. Furthermore, gastrointestinal conditions
such as IBD and IBS have been associated with alter-
ations in the gut microbiota, which is thought to be
related to activation of gut pain sensory pathways.72-74
Gut microbiota are also thought to influence bioavailabil-
ity and metabolism of biophenols, suggesting that an
individual's microbiota profile may influence biophenol
treatment efficacy.71 The gut microbiota play an impor-
tant role in the gut-brain axis, which involves a bidirec-
tional communication network between the central
nervous system and the enteric nervous system. This
allows the brain to influence intestinal activities, and the
gut to influence mood, cognition, and mental health,
which may explain the positive effects of resveratrol
biophenols on QoL.75
In this review, 19 articles reported adverse events that
were mild and GIS-related such as nausea, difficulty pass-
ing stools, loose stools, bloating, and heart burn. Meta-
analysis found no difference between intervention groups
and placebo and these symptoms are also consistent with
those that people with IBS and IBD commonly experi-
ence due to their underlying disease. Furthermore, no
severe adverse events were associated with the interven-
tion, suggesting that biophenol-rich nutraceuticals are
safe to be used in patients with IBD and IBS and poten-
tial benefits may outweigh possible discomfort. However,
due to included studies in this review being of short dura-
tion (4-12 weeks), caution should be taken if taken for
long-term use.
The evidence identified is limited by small sample
sizes of individual studies, and broad clinical heterogene-
ity of both samples, gastrointestinal pathophysiology, and
intervention types. Although conclusions may be drawn
about the general effect of biophenol-rich nutraceuticals,
the evidence exploring the comparative effects of differ-
ent types of biophenols is more limited, except for pep-
permint oil and resveratrol. Likewise, the current
evidence is insufficient to determine optimal dosing regi-
mens due to clinical and statistical heterogeneity.
Although publication bias was detected for GIS only, it is
likely to also exist for other outcomes in which there
were insufficient studies to generate funnel plots. Publi-
cation bias may have been impacted by the exclusion of
otherwise eligible studies on the basis of publication lan-
guage. Confounding effects of dietary intakes were not
reported or accounted for in multivariable models in the
identified RCTs. As some studies did not report mean
changes or SDs within groups, these values had to be cal-
culated for use in the meta-analysis, and as such, SDs are
often overestimated. Finally, this study did not develop
GRADE clinical recommendations.
RCTs of longer duration of 6 to 12 months, which
explore optimal dosing regimens, and confirm safety are a
priority, as are RCTs which deliver interventions to
patients with SUDD, and explore the effect of sub-types of
IBS. Studies that explore the mechanisms of how
biophenols influence biomarkers and clinical presentation
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of inflammatory-related gastrointestinal conditions are
needed, including exploration of the impact on the micro-
biome. RCTs should be sufficiently powered or allow for
multivariable models to account for confounding factors,
including dietary intake and lifestyle.
Biophenol-rich nutraceutical supplementation used
as an adjuvant therapy appears safe and may improve
GIS, inflammation, oxidative stress, and QoL in patients
with IBD and IBS, with higher certainty of evidence for
peppermint oil for IBS and resveratrol for IBD. Further
research is required to strengthen confidence in the body
of evidence, identify ideal dosing regimens, and confirm
long-term safety.
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